Eli Lilly and Company $LLY Stock: MGO One Seven LLC Cuts Holdings

Key Points

• MGO One Seven LLC reduced its Eli Lilly stake by 6.6% in the third quarter, selling 1,708 shares and retaining 24,196 shares valued at approximately $28 million. Institutional investors collectively own 82.53% of the company.
• Eli Lilly reported strong third-quarter results, with revenue rising 38.6% year over year to $24.4 billion and EPS of $7.48, well above analyst expectations. The company also raised its 2026 revenue forecast to $91 billion-$92 billion, supported by continued Mounjaro and Zepbound demand.
• Analyst sentiment remains bullish, but valuation risks are elevated. The stock has a consensus “Moderate Buy” rating and an average price target of $1,398.43, while shares trade near their 12-month high with a price-to-earnings ratio of 45.95.

MGO One Seven LLC lowered its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 6.6% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 24,196 shares of the company's stock after selling 1,708 shares during the quarter. MGO One Seven LLC's holdings in Eli Lilly and Company were worth $27,997,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Aprio Wealth Management LLC boosted its stake in shares of Eli Lilly and Company by 3.9% during the 3rd quarter. Aprio Wealth Management LLC now owns 7,326 shares of the company's stock worth $8,476,000 after purchasing an additional 274 shares during the last quarter. Modera Wealth Management LLC raised its position in shares of Eli Lilly and Company by 6.5% in the third quarter. Modera Wealth Management LLC now owns 48,573 shares of the company's stock valued at $56,202,000 after buying an additional 2,976 shares during the last quarter. Greenup Street Wealth Management LLC boosted its position in Eli Lilly and Company by 37.0% during the third quarter. Greenup Street Wealth Management LLC now owns 4,131 shares of the company's stock worth $4,780,000 after acquiring an additional 1,115 shares during the last quarter. CFC Planning Co LLC boosted its position in Eli Lilly and Company by 53.5% during the third quarter. CFC Planning Co LLC now owns 2,547 shares of the company's stock worth $2,949,000 after acquiring an additional 888 shares during the last quarter. Finally, Petros Family Wealth LLC grew its stake in Eli Lilly and Company by 4.2% in the 3rd quarter. Petros Family Wealth LLC now owns 601 shares of the company's stock worth $695,000 after acquiring an additional 24 shares during the period. Hedge funds and other institutional investors own 82.53% of the company's stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q3 results substantially beat expectations. Revenue rose 39% year over year to $24.4 billion, while adjusted EPS was $7.48 versus the $5.68 consensus estimate. Mounjaro sales increased 65% to $10.7 billion and Zepbound sales rose 49% to $5.35 billion. Lilly third-quarter results
• Positive Sentiment: Lilly raised its 2026 revenue forecast to $91 billion-$92 billion, up from $85 billion-$87 billion previously. Strong demand, broader Medicare access and growing middle-income adoption are supporting expectations for continued GLP-1 expansion. Q3 earnings call highlights
• Positive Sentiment: Analysts raised their price targets and maintained bullish ratings. Scotiabank lifted its target to $1,605 with a “sector outperform” rating, Morgan Stanley raised its target to $1,596 with an “overweight” rating, and RBC moved to $1,600 with an “outperform” rating. Analyst commentary
• Positive Sentiment: Pipeline and portfolio diversification offer additional upside. Positive Phase 3 retatrutide data strengthened Lilly’s competitive position against Novo Nordisk, while oncology, immunology and neuroscience products are beginning to contribute more meaningfully. Lilly growth opportunities
• Negative Sentiment: Investors face execution and valuation risks. Realized prices fell 15%, meaning volume growth must continue to offset pricing pressure. Results also benefited from roughly $900 million in one-time items, and acquired in-process research charges weighed on earnings. With GLP-1 drugs representing a large share of revenue and the stock near its high, expectations are elevated. Reuters earnings report

Eli Lilly and Company Stock Down 0.1%

Shares of Eli Lilly and Company stock opened at $1,415.64 on Monday. Eli Lilly and Company has a twelve month low of $834.19 and a twelve month high of $1,449.68. The company has a fifty day moving average price of $1,197.72 and a 200 day moving average price of $1,092.57. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17. The stock has a market cap of $1.33 trillion, a price-to-earnings ratio of 45.95, a price-to-earnings-growth ratio of 1.80 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating the consensus estimate of $5.71 by $1.77. The business had revenue of $24.40 billion for the quarter, compared to the consensus estimate of $22.58 billion. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The company's revenue was up 38.6% on a year-over-year basis. During the same period last year, the business posted $7.02 EPS. Equities research analysts forecast that Eli Lilly and Company will post 35.18 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company's payout ratio is presently 22.46%.

Wall Street Analyst Weigh In

LLY has been the subject of several analyst reports. Guggenheim boosted their price target on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a "buy" rating in a report on Friday, September 18th. Weiss Ratings lowered Eli Lilly and Company from a "buy (b+)" rating to a "buy (b)" rating in a research note on Friday. Berenberg Bank upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating and set a $1,400.00 price objective on the stock in a report on Tuesday, September 15th. Scotiabank lifted their price objective on Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the company a "sector outperform" rating in a research report on Friday. Finally, Cantor Fitzgerald upped their target price on Eli Lilly and Company from $1,410.00 to $1,440.00 and gave the company an "overweight" rating in a research note on Thursday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $1,398.43.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald Zakrowski sold 2,000 shares of the company's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the transaction, the chief accounting officer directly owned 1,526 shares in the company, valued at approximately $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the company's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares of the company's stock, valued at $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 13,500 shares of company stock valued at $15,958,170. Corporate insiders own 0.14% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.